Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
TOVX Theriva Biologics
0.905+0.005+0.56%
Close
01/27 16:00 ET
0.930+0.025+2.75%
Post Mkt Price 01/27 16:05 ET
High
0.970
Open
0.900
Turnover
135.08K
Low
0.861
Pre Close
0.900
Volume
145.08K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Steven A. Shallcross Purchases 25,000 Shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Stock
Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Get Rating) CEO Steven A. Shallcross acquired 25,000 shares of the firm's stock in a transaction on Wednesday, January 25th. The stock was purchased at an
Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders int
'Theriva Biologics Has Received A Notice Of Allowance For Its U.S. Patent Application 16/982,211 Titled "Alkaline Phosphatase Agents For Treatment Of Radiation Disorders"' - USPTO
'Theriva Biologics Has Received A Notice Of Allowance For Its U.S. Patent Application 16/982,211 Titled "Alkaline Phosphatase Agents For Treatment Of Radiation Disorders"' - USPTO
Maxim Group Reaffirms Their Buy Rating on Theriva Biologics (TOVX)
Theriva Biologics Announces 1st Patient Dosed in VIRAGE Phase 2b Trial
Theriva Biologics Announces First Patient Dosed In VIRAGE, A Phase 2b Trial Of Systemically Administered VCN-01 In Combination With Chemotherapy In Pancreatic Ductal Adenocarcinoma
-Initiation of Phase 2b trial follows clearance from the US Food and Drug Administration (FDA) and Spanish Agency for Medicines and Health Products (AEMPS)--The first patient was dosed in Spain; trial
Sidoti's December Small-Cap Virtual Conference
Presentation Times and Weblinks Released for Over 65 Presenting CompaniesWednesday and Thursday, December 7-8, 2022NEW YORK, NY / ACCESSWIRE / December 6, 2022 / Sidoti & Company, LLC has released the
Maxim Group Sticks to Its Buy Rating for Theriva Biologics (TOVX)
Theriva Biologics GAAP EPS of -$0.33
Theriva Biologics Q3 EPS $(0.33) Beats $(0.39) Estimate
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.39) by 15.38 percent. This is a 65 percent decrease over losses of $(0.20)
Company Overview
More
Theriva Biologics, Inc.(formerly Synthetic Biologics, Inc.) is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
CEO： Mr. Steven A. Shallcross
Market： AMEX
Listing Date： 02/12/1993
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet